LLY Jan 2025 590.000 call
| Previous Close | 59.70 |
| Open | 59.70 |
| Bid | 51.60 |
| Ask | 54.50 |
| Strike | 590.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 59.70 - 59.70 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 250 |
ZacksWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ZacksLilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
ReutersLilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer. Lilly has been bolstering its pipeline through small deals as its cancer therapy Alimta faces fierce competition from copycat versions while betting on potential blockbuster drug tirzepatide, or Mounjaro, to drive growth. Point Biopharma is currently testing radioligand therapy candidates, PNT2002 and PNT2003, in late-stage studies.
